SEC Form 4 · accession 0001539937-26-000010
SUPERNUS PHARMACEUTICALS, INC. · SUPN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jack A. Khattar
Officer — President, CEO · Director
Period of report
Jul 29, 2026
Accepted (ET)
Jul 31, 2026 · 5:06 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001356576
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Performance Share UnitF1 | $0.00 | Jul 29, 2026 | A | 29,849 | A | — | — | Common Stock | 29,849 | 29,849 | D |
Explanation of responses
- F1On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.